EX-99.2 3 y16940exv99w2.txt CERTAIN SUPPLEMENTAL INFORMATION EXHIBIT 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2005 ================================================================================ OTHER (INCOME)/EXPENSE, NET (MILLIONS OF DOLLARS)
------------------------------------------------------ 4Q `05 4Q `04 YTD 2005 YTD 2004 -------------------------------------------------------------------------------- INTEREST INCOME $ (166.0) $ (90.2) $ (480.9) $ (300.1) INTEREST EXPENSE 108.2 77.0 385.5 293.7 EXCHANGE (GAINS)/LOSSES 0.4 (28.3) (16.1) (18.4) MINORITY INTERESTS 30.2 40.3 121.8 154.2 Other, net (99.1) (102.7) (120.5) (473.4) -------- -------- -------- -------- TOTAL $ (126.3) $ (103.9) $ (110.2) $ (344.0) -------- -------- -------- --------
JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS) All sales reported here are JV sales, presented on a "NET" basis.
------------------------------------------------------ MERIAL 4Q `05 4Q `04 YTD 2005 YTD 2004 -------------------------------------------------------------------------------- IVOMEC, HEARTGARD, other avermectins $117 $117 $ 468 $ 452 FRONTLINE 144 110 758 679 Biologicals 149 133 533 477 Other Animal Health 57 63 228 228 ---- ---- ------ ------ TOTAL MERIAL SALES $467 $423 $1,987 $1,836 ---- ---- ------ ------
------------------------------------------------------ SANOFI PASTEUR-MSD 4Q `05 4Q `04 YTD 2005 YTD 2004 -------------------------------------------------------------------------------- HEPATITIS VACCINES $ 15 $ 20 $ 81 $ 81 VIRAL VACCINES 18 12 79 54 Other Vaccines 166 189 705 672 ---- ---- ------ ------ TOTAL SANOFI-MSD SALES $199 $221 $ 865 $ 807 ---- ---- ------ ------
------------------------------------------------------ MERCK/SCHERING-PLOUGH COLLABORATION 4Q `05 4Q `04 YTD 2005 YTD 2004 -------------------------------------------------------------------------------- VYTORIN (Worldwide) $355 $ 76 $1,028 $ 132 ZETIA (Worldwide) 391 328 1,397 1,053 ---- ---- ------ ------ TOTAL $746 $404 $2,425 $1,185 ---- ---- ------ ------
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2005 NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
4Q `05 vs. 4Q `04 ---------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------------------------------------------------------------------- AGGRASTAT -3% 21 N/A -- -3% 21 ARCOXIA -28% 55 N/A -- -28% 55 CANCIDAS 19% 157 16% 90 24% 67 COZAAR / HYZAAR 2% 782 2% 270 3% 512 CRIXIVAN / STOCRIN 45% 90 29% 11 47% 79 EMEND 57% 28 43% 23 * 5 FOSAMAX -5% 789 9% 482 -20% 307 INVANZ 43% 27 23% 16 86% 11 MAXALT 3% 94 1% 61 7% 33 PRIMAXIN 9% 191 5% 57 11% 135 PROPECIA 14% 86 3% 36 23% 50 PROSCAR -1% 192 -- 99 -2% 93 SINGULAIR 12% 819 8% 572 21% 246 TIMOPTIC / TIMOPTIC XE -19% 35 -8% 2 -20% 32 TRUSOPT / COSOPT 7% 167 9% 73 5% 94 VASOTEC / VASERETIC -17% 152 N/A -- -17% 152 VIOXX * -- * -- * -- ZOCOR -18% 1,074 -9% 819 -38% 255 HEPATITIS VACCINES 3% 48 -- 38 38% 11 VIRAL VACCINES -1% 134 -2% 120 8% 14 OTHER VACCINES 8% 111 6% 94 13% 17
* 100% or over N/A - Not Applicable TOTAL SALES: VOLUME, PRICE, EXCHANGE
4Q '05 % CHG. VOL PX FX TOTAL PHARMACEUTICAL SALES $5,766 - 1 - -1 ------- ----- ---- ---- ---- U.S. ($ MM) 3,482 3% - 3 N/A Foreign ($ MM) 2,284 -4% 3 -4 -3
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES DECEMBER YEAR-TO-DATE 2005 NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
------------------------------------------------------- DECEMBER YTD `05 vs. DECEMBER YTD `04 ------------------------------------------------------- -------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ -------------------------------------------------------------------------------- AGGRASTAT 3% 88 N/A -- 3% 88 ARCOXIA -5% 218 N/A -- -5% 218 CANCIDAS 33% 570 25% 313 43% 258 COZAAR / HYZAAR 8% 3,037 3% 1,032 10% 2,005 CRIXIVAN / STOCRIN 36% 348 38% 40 36% 308 EMEND 84% 87 71% 74 * 13 FOSAMAX 1% 3,191 3% 1,829 -2% 1,362 INVANZ 49% 94 32% 58 87% 36 MAXALT 12% 348 13% 224 11% 125 PRIMAXIN 15% 740 31% 213 10% 527 PROPECIA 8% 292 -- 129 15% 163 PROSCAR 1% 741 1% 370 2% 371 SINGULAIR 13% 2,976 10% 2,044 21% 932 TIMOPTIC / TIMOPTIC XE -12% 138 7% 10 -13% 128 TRUSOPT / COSOPT 10% 617 5% 248 14% 369 VASOTEC / VASERETIC -13% 623 N/A -- -13% 623 VIOXX * -- * -- * -- ZOCOR -16% 4,382 -13% 3,142 -22% 1,240 HEPATITIS VACCINES -2% 195 -7% 150 22% 44 VIRAL VACCINES 8% 597 6% 536 25% 61 OTHER VACCINES 10% 311 6% 241 23% 70
* 100% or over N/A - Not Applicable TOTAL SALES: VOLUME, PRICE, EXCHANGE
YTD `05 % CHG. VOL PX FX TOTAL PHARMACEUTICAL SALES $ 22,012 -4% -6 1 1 --------- --- --- -- -- U.S. ($ MM) 12,767 -5% -8 3 N/A Foreign ($ MM) 9,245 -2% -2 -2 2